Sri Lanka to procure 2 to 3 mn doses of Covid vaccine from India: Official

Sri Lanka will purchase 2 to 3 million doses of Oxford-AstraZeneca vaccine from its Indian manufacturing company Serum Institute of India during the next two days

Covishield
Representational image of Covishield
Press Trust of India Colombo
2 min read Last Updated : Jan 27 2021 | 2:49 PM IST

Sri Lanka will purchase 2 to 3 million doses of Oxford-AstraZeneca vaccine from its Indian manufacturing company Serum Institute of India during the next two days, a top Sri Lankan official said here on Wednesday.

Lalith Weeratunga, the advisor to President Gotabaya Rajapaksa said that purchasing from India will follow Thursday's arrival of India's free vaccines to Sri Lanka.

He said the Indian Covishield vaccine is to arrive tomorrow and the consignment will be accepted by President Rajapaksa at the Colombo international airport.

A total of 250,000 people, mostly health frontline workers, members of the security forces and police and the vulnerable aged, will get the vaccine on a priority basis.

The vaccination programme for which dry runs were made over the weekend will commence on Friday.

Weeratunga added that 300,000 free vaccines from China are also due and the government would be requesting Russia also for the vaccine.

Sri Lanka has recorded a near 60,000 cases till January 26, with 288 deaths from the pandemic since it was found in the island nation in mid March last year.

India is one of the world's biggest drug makers and an increasing number of countries have already approached it for procuring the coronavirus vaccines.

In the last few days, India has sent consignments of domestically produced coronavirus vaccines under grant assistance to Bhutan, Maldives, Nepal, Bangladesh, Myanmar, Mauritius and Seychelles.

It is also undertaking commercial supplies of the doses to a number of countries, including Saudi Arabia, South Africa, Brazil and Morocco.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirussri lankaCoronavirus TestsCoronavirus Vaccine

First Published: Jan 27 2021 | 2:48 PM IST

Next Story